“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,”
Scientists from the Center for Innovations in Medicine in the Biodesign Institute at Arizona State University have developed a comprehensive, microchip-based technology, called immunosignature diagnosis, which can rapidly and comprehensively measure an individual’s vaccine response, promising to take much of the initial guesswork out of predicting effective vaccines.
Professor Stephen Albert Johnston and Joseph Barten Legutki, used a mouse model of influenza infection to determine how the immunosignature of a natural infection can be used to discriminate between a protective and non-protective vaccine. The study appears in the October 28 early online edition of the Proceedings of the National Academy of Sciences.
Johnston is driven by the quest to develop disruptive technology that could make health care more effective and affordable. Despite 17 percent of the U.S. GDP tied to health care costs and growing, the U.S. does not get as much value per dollar as other countries (spending the most per capita yet ranking last in efficiency). He believes innovative diagnostic technologies that could determine whether or not an individual would get sick before symptoms appear, as well as the early identification of microbial culprits of infections has high potential for transforming medicine.
“We developed the immunosignature technology primarily for early detection of disease, but realized it may have other applications,” said Johnston, who directs the Center for Innovations and Medicine at the Biodesign Institute “In this work we demonstrate that it may also be useful for screening candidate vaccines.”
Currently, the effectiveness of vaccines is evaluated by looking for the presence a particular type of antibody from the vaccine-generated immune response or by extensive and complicated sets of analyses. The power of the immunosignature is that this effectiveness can be completed in one fell swoop, by using thousands of random molecules aligned on a microscope slide, like the transistors on a computer chip.
“We use an array of 10,000 short peptides, each one about twenty amino acids long, to generate a high degree of specificity and sensitivity for measuring both human, dog, and mouse infections and chronic and genetic diseases,” said Legutki, a faculty in CIM and lead author of the paper. “A subset of these peptides will stand out, based on an individual’s antibody repertoire, and provide a unique pattern, or signature for a given disease.”
In the study, they used a mouse H1N1 flu model system. This included both seasonal forms of influenza or inactive control, as well as several commercially available vaccines that could provide full or partial protection, and asked whether or not the immunosignature could predict vaccine effectiveness. They also examined individual differences among those receiving the same vaccine, and whether the immunosignature profile could have the power to reveal what parts of influenza virus were doing the most harm.
They found that the live and inactive forms of the virus produced different immunosignatures, with different intensities of immune response, yet both contained a core immunosignature of the virus.
Go deeper with Bing News on:
- Feed has no items.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Medicines For Monkeypox - Antivirals And Vaccines Are Available
We have two antivirals and two vaccines available to treat monkeypox, but we need to work carefully to control the infection's spread.
- Agriculture Ministry commences production of FMD vaccine
The Center for Pharma Veterinary (Pusvetma) of the Ministry of Agriculture has begun producing a vaccine for foot and mouth disease (FMD) in livestock to ...
- Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today provided an update on the clinical ...
- Moderna enters monkeypox vaccine development
with 34 vaccines in the development. On Monday, five more countries reported their first confirmed monkeypox infections taking the total number of countries to report the outbreak to 17 this year.
- Japanese Encephalitis Vaccines Market Growing Trade Among Emerging Trend, Strategic Development and New Opportunities 2022-2029
The ”Japanese Encephalitis Vaccines Market” report provides a comprehensive analysis of growth opportunities in ...